Three FDA Device Approvals in October 2026 That Patients Will Notice

October brought three FDA decisions that change what care can look like: a heart valve that grows with a child, an automated insulin pump now open to adults with type 2 diabetes, and a heart failure monitor that puts pressure readings on the patient's phone.
A heart valve that grows with the child
On October 1, the FDA approved the first heart valve designed to grow with children, the Autus Size-Adjustable Valve. It is for young patients with congenital pulmonary valve disease, such as pulmonary valve stenosis or atresia.
Surgeons implant it at about 13 mm, a size that suits toddlers and preschoolers. As the child grows, a small balloon catheter widens it, up to about 22 mm, roughly adult size. The leaflets are made of a polymer rather than animal tissue, which the FDA notes tends to wear out faster in children.
The pitch is fewer repeat operations. In the pivotal study of 62 children at 12 U.S. sites, the first 60 patients had acceptable blood flow and no more than mild backflow at six months, with no deaths, strokes or clot complications needing treatment.
The FDA is also candid about the limits. Three patients had a fracture in the valve frame and two had reduced leaflet movement, none with symptoms. Two children whose valves began to deteriorate as they outgrew them were expanded without invasive surgery, but experience is still limited and longer-term studies continue.
Automated insulin delivery reaches type 2 diabetes
On October 16, Sequel Med Tech announced that its twiist automated insulin delivery system was cleared for adults with insulin-treated type 2 diabetes. The system had been cleared for type 1 diabetes in March 2024, so this opens it to a much larger group of people.
It adjusts background insulin automatically toward targets set by the user and their care team. The algorithm is based on Tidepool Loop, and the pump works with continuous glucose monitors including Abbott's FreeStyle Libre 3 Plus and Senseonics' Eversense 365.
In a 13-week multicenter trial published in Diabetes Care, average HbA1c fell from 8.1% to 7.4%, and time in the target glucose range rose from 57% to 73%. Most participants had never used an automated system or counted carbs, and many improved within 24 hours of starting.
Heart failure monitoring moves to the patient's phone
Abbott announced on October 5 that the FDA approved updates to its CardioMEMS HF System. Patients with the implanted sensor will be able to see their pulmonary artery pressure readings and trends in an app called CardioGuide HF on iOS or Android. Abbott expects the patient-facing features later this year.
Pressure in the pulmonary artery can rise before symptoms like shortness of breath or swelling appear. Until now, those readings went to the clinical team. Clinicians can also set a personalized medication plan in Abbott's Merlin.net portal, and when the care team enables it, instructions based on pressure changes are sent to the patient's app.
One caveat: Abbott has not reported an outcomes study of the new app features, so effects on hospitalizations and engagement are not yet established.
What these approvals have in common
All three are about care that adapts to the patient instead of the other way around: a valve that expands with growth, a pump that adjusts dosing automatically, and a sensor whose data now reaches the person it belongs to.
They also show how different FDA pathways can be. The Autus valve went through premarket approval (PMA), the agency's most stringent route, and carried Breakthrough Device designation. The twiist expansion was a 510(k) clearance, which compares a device to one already on the market. Approval and clearance are not interchangeable words, and each reflects a different level of evidence.
This post summarizes public information as of October 30, 2026 and is not medical advice.




